Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Madrigal contributed positively to relative performance, supported by very strong sales of Rezdiffra, the first FDA-approved medication for MASH, alongside positive physician adoption and payer reception.
— Nick Schommer, Brian Recht
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Madrigal Pharmaceuticals, Inc.
No other institutional pitches found for this ticker yet.